1. Introduction {#sec1}
===============

Atrial fibrillation (AF) is a major healthcare problem worldwide which has enormous economic and public health implications. AF is associated with an increased risk of stroke, heart failure, and all-cause mortality \[[@B1]--[@B3]\].

Surgical ablation was introduced as a treatment option by Cox et al. \[[@B4]\] in 1991, and it is currently an effective curative strategy for AF. Haïssaguerre et al. \[[@B5]\] suggested that ectopic beats from pulmonary veins may cause AF, and the field of pulmonary vein isolation (PVI) was consequently established and is now performed via catheter or surgical ablation \[[@B6]\]. Left ablation (LA) has historically been the main method used to treat AF, and it has a fairly good clinical effect \[[@B7], [@B8]\]. However, some studies have suggested that LA is less efficacious than biatrial ablation (BA), especially when a right-side AF trigger is present \[[@B9]\]. Hence, because outcomes have been inconclusive, Phan et al. \[[@B10]\] and Zheng et al. \[[@B11]\] reported relevant meta-analyses in 2014, but they arrived at a different conclusion. The authors showed that BA was more effective than LA and that the rate of permanent pacemaker implantation was also higher in the BA cohort than in the LA cohort. However, Zheng et al. \[[@B11]\] suggested that the effects of BA and LA are the same.

In the past two years, several other studies \[[@B8], [@B12]--[@B15]\] have compared BA and LA in AF, with controversial outcomes. Hence, in this meta-analysis, we sought to assess the current evidence available on this issue.

2. Methods {#sec2}
==========

2.1. Literature Search Strategy {#sec2.1}
-------------------------------

Electronic searches were performed in August 2016 without search restrictions. The primary sources were the electronic Medline, PubMed, Cochrane Library, and EMBASE databases, which were searched from their date of inception to August 2016. The following search terms were used: "maze," "biatrial," "bi-atrial," "uniatrial," "left atrial," and "ablation." When duplicate published trials with accumulating numbers of patients or increased lengths of follow-up were encountered, the most recent or most complete report was considered. All titles and abstracts identified in the electronic search were uploaded into an EndNote (version X7; Thomson Corporation, Stanford, USA) database ([Figure 1](#fig1){ref-type="fig"}).

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

All available randomized, controlled trials (RCTs) and retrospective comparative studies that compared BA with LA in all age groups were included. Abstracts, case reports, conference presentations, editorials, reviews, and expert opinions were excluded. When institutions published duplicate studies with accumulating numbers of patients or increased lengths of follow-up, only the most complete report was included. Reference lists were also manually searched for further relevant studies.

2.3. Data Extraction and Critical Appraisal {#sec2.3}
-------------------------------------------

Two reviewers (Hongmu Li and Xifeng Lin) conducted data extraction independent of the included studies. Data on authorship, year of publication, study design, study population, baseline characteristics, characteristics related to outcomes, and duration of follow-up were extracted from each study. Reported percentages were approximated to numbers. The risk of bias was assessed using the Downs and Black checklist \[[@B16]\] for randomized and observational studies. Discrepancies between the reviewers were resolved by discussion until consensus was reached. The final results were reviewed by the senior investigator (Ping Hua).

2.4. Quality Assessment and Statistical Analysis {#sec2.4}
------------------------------------------------

The included studies were rated to determine the level of quality of the provided evidence according to the criteria of the Centre for Evidence-Based Medicine in Oxford, UK \[[@B17]\]. The methodological quality of the RCTs was assessed with the Cochrane risk of bias tool \[[@B18]\]. The methodological quality of retrospective studies was assessed with the modified Newcastle-Ottawa scale \[[@B19], [@B20]\].

This meta-analysis was performed using Review Manager Version 5.3 (Cochrane Collaboration, Oxford, UK). Dichotomous variables from individual studies were analyzed using odds ratios (ORs) with 95% confidence intervals (CIs). *Q*-statistics (*P* \< 0.10) or*I*^2^ statistics were performed to test for heterogeneity between included studies, and values of 50% or higher were considered to be indicative of substantial heterogeneity. If there was substantial heterogeneity, the possible clinical and methodological reasons for this were explored qualitatively. Publication bias was examined through a visual inspection of funnel plots and assessed by applying Egger\'s weighted regression statistic and considering a *P* value less than 0.05 as indicating significant publication bias. A *P* value of less than 0.05 was considered statistically significant for all analyses.

2.5. Synthesis of Evidence {#sec2.5}
--------------------------

Our electronic literature search resulted in the retrieval of 398 citations. Of these, 372 were excluded after duplicate and irrelevant references were excluded, and 49 potentially relevant articles were retrieved. Finally, following a manual search of reference lists and a critical appraisal, 21 studies comprising 3609 patients were included in this meta-analysis. Two articles had redundant publications but covered different characteristics \[[@B21], [@B22]\].

2.6. Quality Assessment and Baseline Characteristics of Eligible Studies {#sec2.6}
------------------------------------------------------------------------

In all, 21 studies were included in this meta-analysis, including three prospective randomized trials \[[@B23]--[@B25]\], five prospective observational studies \[[@B13], [@B26]--[@B29]\], and 13 retrospective observational studies \[[@B8], [@B12], [@B14], [@B15], [@B21], [@B22], [@B30]--[@B36]\]. The risk of bias in each study is shown in [Figure 2](#fig2){ref-type="fig"} and [Table 1](#tab1){ref-type="table"}. Among the 3609 patients, 1901 received BA, and 1708 received LA. Patients in the BA group underwent a classical or modified maze procedure, including both left-sided and right-sided maze procedures. However, patients in the LA group underwent a left-sided maze procedure that included PVI, left atrial posterior wall isolation, mitral isthmus ablation, and left atrial appendage excision.

Three studies used cryoablation energy \[[@B15], [@B27], [@B31]\], eleven studies used radiofrequency energy \[[@B12]--[@B14], [@B21], [@B23], [@B25], [@B26], [@B29], [@B32]--[@B34]\], and the remaining studies used a combination of different energy sources, including radiofrequency, cryoablation, and microwave and "cut-and-sew" \[[@B8], [@B22], [@B24], [@B28], [@B30], [@B35], [@B36]\]. Concomitant coronary artery bypass grafting surgery was reported in 10 studies \[[@B8], [@B13], [@B21], [@B22], [@B25], [@B27]--[@B31], [@B36]\], while a concomitant valvular operation was performed in other included studies. The baseline characteristics of the patients in the included studies are shown in Tables [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"}.

3. Outcomes {#sec3}
===========

3.1. Assessment of Efficacy {#sec3.1}
---------------------------

The data were pooled from 16 studies \[[@B12]--[@B15], [@B21]--[@B26], [@B28], [@B29], [@B31]--[@B33], [@B36]\] that assessed the efficacy of restoring sinus rhythm (SR), and the results showed that there was no significant difference between the BA and LA groups at discharge (78.3% versus 73.86%; OR: 1.02; 95% CI: 0.69--1.51; *P* = 0.92;*I*^2^ = 66%). However, the overall prevalence of SR was higher in the BA group than in the LA group at a 6-month follow-up (78.82% versus 69.67%; OR: 1.54; 95% CI: 1.17--2.03; *P* = 0.002;*I*^2^ = 0%) \[[@B14], [@B15], [@B22], [@B24]--[@B26], [@B30]--[@B32], [@B36]\]. For patients with a follow-up at 12 months \[[@B8], [@B14], [@B15], [@B26], [@B27], [@B30], [@B31], [@B34]\] and after more than 1 year \[[@B12], [@B15], [@B23]--[@B25], [@B31]\], the prevalence of SR in the BA group was similar to that in the LA group (63.01% versus 65.47%; OR: 1.31; 95% CI: 0.70--2.48; *P* = 0.40;*I*^2^ = 77%). The weighted average mean follow-up for studies reporting SR after more than 1 year was 23.3 months. These results are shown in [Figure 3](#fig3){ref-type="fig"}.

3.2. Mortality and Major Complications {#sec3.2}
--------------------------------------

Eight studies with 1185 patients investigated mortality after the BA or LA procedure. When effects were pooled, there was no significant difference in either early mortality \[[@B8], [@B14], [@B23], [@B27]--[@B29], [@B33]\] (\<30 days, OR: 1.02; 95% CI: 0.36--2.90; *P* = 0.97;*I*^2^ = 31%, [Figure 4](#fig4){ref-type="fig"}) or late mortality \[[@B23], [@B27], [@B29], [@B31], [@B35]\] (OR: 2.31; 95% CI: 0.86--6.22; *P* = 0.10;*I*^2^ = 0%, [Figure 5](#fig5){ref-type="fig"}) between the BA and LA groups.

There was no significant increase in the risk of cerebrovascular events \[[@B8], [@B27], [@B28], [@B31]\] between the two groups (OR: 0.61; 95% CI: 0.16--2.40; *P* = 0.48;*I*^2^ = 0%, [Figure 6](#fig6){ref-type="fig"}). In eight studies that compared LA with BA, BA increased the risk of permanent pacemaker implantation \[[@B22], [@B23], [@B30], [@B31], [@B33], [@B36]\] (OR: 2.46; 95% CI: 1.55--3.91; *P* = 0.0001;*I*^2^ = 0%, [Figure 7](#fig7){ref-type="fig"}). No heterogeneity was observed.

3.3. Sensitivity Analysis and Publication Bias {#sec3.3}
----------------------------------------------

The risk of bias was comprehensively assessed according to the guidelines of the Cochrane Collaboration, and neither visual inspection of funnel plots nor Egger\'s test detected significant publication bias for the major outcomes explored in this meta-analysis, including the prevalence of SR at discharge (*t* = 0.04; *P* = 0.972), SR at a 6-month follow-up (*t* = 0.27; *P* = 0.791), SR at a 12-month follow-up (*t* = 0.90; *P* = 0.401), SR after more than 1 year (*t* = 0.52; *P* = 0.626), early mortality (*t* = 1.03; *P* = 0.363), late mortality (*t* = −1.07; *P* = 0.397), neurological events (*t* = 51.13; *P* = 0.012), and permanent pacemaker implantation (*t* = 2.42; *P* = 0.060). To evaluate the effect of heterogeneity on the pooled effect, we carried out a sensitivity analysis. Sensitivity and subgroup analyses found no significant heterogeneity ([Table 4](#tab4){ref-type="table"}).

4. Discussion {#sec4}
=============

Two recent meta-analyses \[[@B10], [@B11]\] that compared BA, LA, and surgical ablation in AF arrived at conflicting conclusions. However, these meta-analyses excluded several studies that compared BA with LA \[[@B8], [@B12]--[@B15], [@B25]\]. Therefore, we performed a new meta-analysis to compare BA with LA. This meta-analysis included three RCTs and 18 retrospective studies that collectively contained 3609 patients and compared the efficacy and safety of BA and LA. There was no significant difference between BA and LA in the rate of restored SR, but BA groups had a higher probability of SR after 6 months of follow-up. We also found that while BA and LA had similar rates of death and cerebrovascular events, the BA groups had a higher rate of permanent pacemaker implantation.

A pooled analysis of restored postoperative SR showed that there was no difference between the BA and LA groups. However, several recent studies \[[@B21], [@B23], [@B36]\] have shown that BA is inferior to the more complete LA when used alone. Patients in the LA group had shorter aortic cross-clamping times and cardiopulmonary bypass times than were observed in the BA group. Furthermore, the techniques used in AF ablation vary widely, even within the same procedure group, and if the different lesion sets used for ablation were included, the results may have indicated that this procedure has greater efficacy.

In contrast, some studies have reported that BA is superior to LA for restoring SR \[[@B8], [@B12], [@B15], [@B25]--[@B28], [@B30]--[@B33]\]. This finding rests mainly on the finding that BA groups have much more tissue damage and a higher rate of cardiac conduction system injury. However, all of these studies have common limitations. First, some patients took antiarrhythmic drugs (including amiodarone) perioperatively and continued the use of these drugs until the operation, and few researchers sufficiently addressed this variable. Second, the sample size in most of the articles was small (less than 150 individuals), weakening the power of the studies. Third, long rhythm registration during follow-up was not available in all of the patients. Furthermore, only a few of the studies were RCTs. Unlike previous reviews, we included the largest studies in our meta-analysis, and our inclusion criteria did not limit our search to articles published in English. We also conducted a subgroup analysis of RCT and non-RCT studies and of small-sample and large-sample studies to assess the effect of heterogeneity on the pooled effect estimate.

The findings of the present meta-analysis confirm that BA increases the risk of permanent pacemaker implantation. This finding may be attributed to the fact that LA has shorter aortic cross-clamping and cardiopulmonary bypass times and promotes more extensive lesions. There was no significant increase in the risk of cerebrovascular events or early and late mortality between the two groups. We hypothesize that report selection resulted in fewer such events, and these results remain to be discussed.

The most important findings of our meta-analysis include the following: (1) LA and BA were equally effective in restoring SR, (2) BA resulted in higher prevalence of SR at the 6-month follow-up, and (3) unlike previous analyses, this meta-analysis included the largest studies, and its inclusion criteria did not limit the search to articles published in the English language.

The results of our study show that there was no difference in the rate of restored SR between LA and BA. While some previous studies have proposed that BA alone is inferior to a more complete LA, this significance disappeared in a multivariate analysis. The difference in these results may have been caused by differences in inclusion criteria between previous studies and our study. The other studies limited inclusion to articles reported in the English language. Additionally, the techniques used for AF ablation varied widely, including, for example, the use of different lesion sets, even within same procedure group.

One of the most important reasons that researchers have suggested for why BA is better than LA at restoring SR is that there is a significant difference in electrical activity between patients with chronic and paroxysmal AF \[[@B37], [@B38]\]. Lazar et al. \[[@B37]\] demonstrated that a left-to-right atrial frequency gradient exists in paroxysmal but not persistent AF. This prompted them to propose that the maintenance of persistent or chronic AF may be less dependent on the posterior left atrium. Additionally, Sanders et al. \[[@B39]\] proposed that, in patients with paroxysmal AF, the dominant sources of activity are often localized in the pulmonary veins. In contrast, in patients with permanent AF, the dominant sites are more often localized in the atria, including right atrial sites. Unsurprisingly, patients with persistent or long-standing persistent AF are more likely to receive BA, and this may affect clinical outcomes \[[@B25]\].

The present meta-analysis has the following limitations. Its main limitation is that only three small-sample RCTs were included. Inadequate random sequence generation and blinding tend to increase the risk of bias. Hence, larger RCTs are needed to determine the best treatment. Another limitation is that the original meta-analysis was based on the assumption that the surgical subgroups (BA and LA) were sufficiently similar to be assessed together, but the operation methods and ablation technologies used in these procedures are continually developing. Additionally, there was extreme heterogeneity among the studies in study design, data, and energy source, and a subgroup analysis yielded results that differed from those obtained in the original analysis. Future systematic reviews should, when sufficient literature is available, evaluate different indications separately. Finally, follow-up periods were generally short. Therefore, the long-term outcomes of BA and LA remain to be explored.

5. Conclusion {#sec5}
=============

In this comparative meta-analysis, we show that BA is not more efficacious than LA in restoring SR. Additionally, the risks of death and cerebrovascular events are significantly different between BA and LA, but BA results in a higher rate of permanent pacemaker implantation.
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###### 

Risk of bias in observational studies.

  Study                     Selection   Comparability   Outcome   Quality score                            
  ------------------------- ----------- --------------- --------- --------------- ------------ ----- ----- ---------
  Gualis et al. 2016        No          Yes             Yes       1, 2            5, 8         Yes   No    ★★★★★
  Liu et al., 2015          No          Yes             Yes       1, 2            5, 8         No    Yes   ★★★★★
  Henn et al., 2015         No          Yes             Yes       NR              5, 6         Yes   No    ★★★★
  Pecha et al., 2014        No          Yes             Yes       1, 2            5, 8         Yes   NR    ★★★★★
  Jiang, 2014               No          Yes             Yes       1, 2            8            Yes   No    ★★★★
  Soni et al., 2013         No          Yes             Yes       1, 2            8            No    No    ★★★
  Pecha et al., 2014        No          Yes             Yes       1, 2            5, 6         Yes   Yes   ★★★★★★
  Onorati et al., 2011      No          Yes             Yes       1, 2            5, 6, 8      Yes   Yes   ★★★★★★★
  Kim et al., 2011          No          Yes             Yes       1, 2            7, 8         Yes   No    ★★★★★
  Breda et al., 2011        No          Yes             Yes       1, 2            6, 8         No    No    ★★★★
  Albage et al., 2011       No          Yes             Yes       1, 2            7            Yes   No    ★★★★
  McCarthy et al., 2010     No          Yes             Yes       1, 2            8            Yes   Yes   ★★★★★★
  Deneke et al., 2009       No          Yes             Yes       1, 4            6, 8         Yes   Yes   ★★★★★★
  Geuzebroek et al., 2008   No          Yes             Yes       1, 2            5            No    Yes   ★★★★
  Deneke et al., 2007       No          Yes             Yes       1, 4            8            Yes   Yes   ★★★★★
  Ryan et al., 2004         No          Yes             Yes       NR              5, 6, 7, 8   Yes   No    ★★★★★
  Guden et al., 2003        No          Yes             Yes       1, 2, 3         NR           Yes   Yes   ★★★★★
  Takami et al., 1999       No          Yes             Yes       1, 2, 3         5, 7, 8      Yes   Yes   ★★★★★★★

NR: no report; comparability variables: 1 = age; 2 = gender; 3 = body mass index; 4 = type of AF; 5 = Euro score; 6 = preoperative antiarrhythmic drugs; 7 = anatomic complexity (more than one artery and/or vein); 8 = single surgeon.

###### 

Characteristics of the studies that were initially included in the meta-analysis.

  First author   Year   Country       Study period   Type of study   Follow-up (MO)                     *n*  (BA)   *n*  (LA)   Type of ablation      Lesion set                        Cardiac operation
  -------------- ------ ------------- -------------- --------------- ---------------------------------- ----------- ----------- --------------------- --------------------------------- ----------------------------------
  Gualis         2016   Spain         2006--2011     R               36                                 67          83          CY                    PVI, LAA, RAA, TC, CS, WG         AVR AVP MVR MVP TVP
                                                                                                                                                                                        
  Liu            2015   China         2012-2012      R               3--12R                             86          111         RF                    PVI, LAA, RAA                     MVR DVR TVP
                                                                                                                                                                                        
  Henn           2015   USA           2002--2014     P, non-RCT      5 years                            532         44          RF                    PVI, LAA, RAA, TC, CS, WG         AVR CABG MVR MVP TVP
                                                                                                                                                                                        
  Pecha          2014   Germany       2008--2011     R               12                                 66          66          RF, CY                LVI, LAA, CI, RAA, TC             CABG AVR MVR TVR
                                                                                                                                                                                        
  Jiang          2014   China         2008--2012     R               NR                                 61          48          RF                    PVI, MV, LAA, RAA, TC, CS, WG     MVR MVP TVP
                                                                                                                                                                                        
  Soni           2013   USA           2007--2011     R               12                                 91          214         RF, CY, MW            PVI, PW, MI, LAA MM               AVR MVR CABG MVP TVP
                                                                                                                                                                                        
  Pecha          2014   Germany       2003--2012     R               30 days                            131         463         CY, RF                LVI, LAA, BLI, CI, RAA, TC        AVR AVP MVR MVP TVP CABG ASD VSD
                                                                                                                                                                                        
  Onorati        2011   Italy         2003--2008     P, non-RCT      15                                 109         32          RF                    PVI MV LAA RAA TC CS WG           AVR AVP MVR MVP TVP
                                                                                                                                                                                        
  Kim            2011   South Korea   2006--2009     R               26 ± 13.3                          199         82          CY                    PVI, PW, MI, LAA, MM, CS          AVR AVP MVR MVP TVP CABG ASD VSD
                                                                                                                                                                                        
  Breda          2011   Brazil        2003--2009     R               12.16 ± 10.89                      15          15          RF                    PVI, PW, MI, LAA, MM              MVR MVP
                                                                                                                                                                                        
  Albage         2011   Sweden        2005--2010     P, non-RCT      1--12R                             44          71          CY                    PVI, PW, MI, LAA, Maze III        AVR CABG MVP TVP MVR ASD MVP
                                                                                                                                                                                        
  McCarthy       2010   USA           2004--2008     P, non-RCT      5--24R                             91          75          RF, CY, cut-and-sew   PVI LAA RAA TC                    AVR MVR TVP CABG
                                                                                                                                                                                        
  Deneke         2009   Germany       NR             R               55 ± 17                            64          66          RF                    PVI, PW, MI, LAA, Maze III        MVR, AVR, CABG
                                                                                                                                                                                        
  Wang           2009   China         2004--2007     P, RCT          28 ± 5                             150         149         RF                    PVI, PW, MI, LAA, CTI, MM         MVR AVR MVP TVR TVP AVP
                                                                                                                                                                                        
  Srivastava     2008   India         NR             P, RCT          44                                 40          40          RF, CY                PVI, PW, MI, LAA, Maze III        MVR AVR MVP TVR TVP AVP
                                                                                                                                                                                        
  Geuzebroek     2008   Netherlands   1999--2005     R               NR                                 26          40          RF                    PVI, PW, MI, LAA, Maze III        MVR AVR MVP TVR TVP AVP
                                                                                                                                                                                        
  Deneke         2007   Germany       1997--2005     R               21                                 106         116         RF                    PVI MV LAA RAA, MM                MVR MVP CABG AVR
                                                                                                                                                                                        
  Calo           2006   Italy         NR             P, RCT          15 ± 5 (BA)/13 ± 6 (LA)            39          41          RF                    PVI MV LAA RAA TC CS WG           NR
                                                                                                                                                                                        
  Ryan           2004   USA           1996--2003     R               595 ± 750 days                     36          7           RF, CY, cut-and-sew   PVI, PW, MI, LAA, Maze III        NR
                                                                                                                                                                                        
  Guden          2003   Turkey        2001           P, non-RCT      10.9 ± 5.58                        48          57          RF                    PVI, PW, MI, LAA, Maze III        AVR CABG MVP TVP MVR ASD MVP
                                                                                                                                                                                        
  Takami         1999   Japan         NR             R               34.1 ± 11.3 (BA)/17.8 ± 3.8 (LA)   30          20          CY, cut-and-sew       PVI, PW, MI, LAA, CTI, Maze III   MVR, CABG, AVR, TVR

MO: month; R: range; P: p retrospective observational; RCT: randomized, controlled trial; BA: biatrial ablation; LA: left atrial ablation; CY: cryoablation; RF: radiofrequency ablation; MW: microwave ablation; PVI: pulmonary vein isolation; LAA: left atrial appendage; RAA: right atrial appendage; TC: terminal crest; CS: coronary sinus; WG: Waterston\'s groove; MI: mitral isthmus; MM: modified maze; CI: cavotricuspid isthmus; PW: posterior wall; AVR: aortic valve replacement; AVP: aortic valvuloplasty; MVR: mitral valve replacement; MVP: mitral valvuloplasty; TVP: tricuspid valvuloplasty; CABG: coronary artery bypass grafting; ASD: atrial septal defect repair; VSD: ventricular septal defect repair; NR: no report.

###### 

Baseline characteristics of the included studies.

  First author   Age (BA/LA, years)           Male (BA/LA)   Diabetes (BA/LA)   Heart failure (BA/LA)   Cerebrovascular events (BA/LA)   Hypertension (BA/LA)   Type of AF
  -------------- ---------------------------- -------------- ------------------ ----------------------- -------------------------------- ---------------------- ---------------------------------
  Gualis         65.1 ± 10.2/71.6 ± 6.8       29/39          15/17              32/31                   7/12                             NR                     Permanent persistent
  Liu            49.87 ± 8.96/47.98 ± 8.64    21/23          NR                 NR                      NR                               NR                     Permanent persistent
  Henn           64 ± 12                      NR             NR                 NR                      NR                               NR                     Permanent persistent
  Pecha          70.5 ± 7.3/70.1 ± 7.5        45/40          16/13              NR                      NR                               NR                     Paroxysmal persistent permanent
  Jiang          52.7 ± 4.9/50.7 ± 5.9        22/21          7/8                36/29                   2/2                              11/8                   Paroxysmal persistent permanent
  Soni           NR                           NR             NR                 NR                      NR                               NR                     Paroxysmal persistent permanent
  Pecha          59 ± 28/68 ± 12              54/116         16/40              NR                      NR                               67/118                 Paroxysmal persistent permanent
  Onorati        64 ± 9/65 ± 8                79/18          40/10              NR                      NR                               37/15                  Permanent persistent
  Kim            56.3 ± 12.0/52.1 ± 11.9      75/47          19/5               NR                      NR                               32/21                  Paroxysmal persistent permanent
  Breda          60.0 ± 8.07/46.3 ± 9.54      9/5            NR                 10/6.                   NR                               NR                     Permanent persistent
  Albage         64.9 ± 10.4/66.9 ± 6.7       34/54          4/11               17/28                   2/7                              10/27                  Paroxysmal persistent permanent
  McCarthy       68.7 ± 10.3/66.8 ± 12.1      42/88          13/22              NR                      NR                               NR                     Paroxysmal persistent permanent
  Wang           67 ± 8/69 ± 9                NR             NR                 NR                      NR                               NR                     Permanent persistent
  Deneke         53.4 ± 10.8/54.2 ± 10.1      54/62          NR                 NR                      NR                               NR                     Permanent persistent
  Srivastava     37.11 ± 11.12/36.03 ± 7.99   19/22          NR                 NR                      NR                               NR                     Permanent persistent
  Geuzebroek     63.3 ± 7.9/61.1 ± 10.3       21/17          NR                 NR                      NR                               NR                     Paroxysmal persistent permanent
  Deneke         68 ± 9                       NR             NR                 NR                      NN                               NR                     Paroxysmal persistent permanent
  Calo           57.9 ± 8.9/59.2 ± 9.1        26/26          NR                 NR                      NR                               16/18                  Paroxysmal persistent permanent
  Ryan           NR                           NR             NR                 NR                      NR                               NR                     Paroxysmal persistent permanent
  Guden          52 ± 11/54 ± 9               14/23          NR                 NR                      N                                NR                     Permanent persistent
  Takami         54.7 ± 8.8/58.3 ± 8.7        11/9           NR                 NR                      NR                               NR                     Paroxysmal persistent permanent

BA: biatrial ablation; LA: left atrial ablation; NR: no report.

###### 

Sensitivity and subgroup analyses.

  Endpoint               Restored SR at discharge   Restored SR at 12 months   Restored SR beyond 1 year                                           
  ---------------------- -------------------------- -------------------------- --------------------------- ------------------- ------------------- -------------------
  *Study design*                                                                                                               0.46                1.37 (0.60, 3.11)
   RCT                   0.38                       0.51 (0.12, 2.25)          Have no RCT studies         0.69                1.25 (0.43, 3.65)   
   Non-RCT               0.4                        1.17 (0.81, 1.68)                                                                              
  *Study size*                                                                                                                                      
   \<150                 0.88                       1.05 (0.56, 1.95)          0.04                        1.76 (1.02, 3.04)   0.76                1.22 (0.24, 4.46)
   \>150                 0.96                       0.99 (0.66, 1.49)          0.44                        1.29 (0.67, 2.48)   0.3                 1.44 (0.73, 2.85)
  *Statistical models*                                                                                                                              
   Fixed-effect          0.3                        1.12 (0.90, 1.38)          0.009                       1.39 (1.09, 1.79)   0.16                1.21 (0.92, 1.59)
   Random-effect         0.34                       1.15 (0.86, 1.55)          0.2                         1.37 (0.85, 2.21)   0.4                 1.31 (0.70, 2.48)

SR: sinus rhythm; RCT: randomized, controlled trial.
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